Titomic’s Cold Spray Adoption Is Broadening—But Is It Becoming a Scalable Defense Business?

August 1, 2026

·

Titomic is accumulating credible cold-spray adoption signals across aerospace repair, allied defense research, U.S. military sustainment and space evaluation. The challenge is no longer proving that the technology has applications. It is proving that those applications can become a scalable and financially efficient business.

During 2026, Titomic secured a repeat order from Lufthansa Technik, sold a multi-pressure cold-spray package to Royal NLR, signed a Space Act Agreement with NASA and established a multi-year research framework with a U.S. military organization.

These are stronger signals than isolated demonstrations because several involve repeat customers, paid equipment purchases and institutional pathways into defense and aerospace programs. However, Titomic remains an early-stage company with a cost base far larger than current revenue.

Addithive verdict

Thesis status: Commercial validation is improving; financial scalability remains unproven.

Titomic is building a differentiated position in repair, coatings and defense manufacturing. The next proof points are repeat production revenue, higher system utilization, improving gross margin and a narrowing operating cash deficit.

What changed?

Lufthansa Technik ordered additional cold-spray capability worth more than A$1.2 million.
The Lufthansa relationship has now been operating for approximately five years, making this a repeat-capacity order rather than a first trial.
Royal NLR ordered low-, medium- and high-pressure cold-spray systems for €1.02 million.
Titomic signed a Space Act Agreement with NASA for testing and evaluation of cold-spray components.
Titomic USA signed a multi-year CRADA with a U.S. military research organization covering defense modernization, sustainment and materials development.
An existing US$1.7 million defense-prime development contract is intended to validate manufacturing pathways for next-generation defense articles.
The six months to December 2025 produced A$4.0 million of customer revenue, while the company remained deeply loss-making.
Cash was A$35.8 million at December 2025 following the earlier A$50 million capital raise.

Why the Lufthansa order matters

Repeat orders are among the most useful adoption signals in additive manufacturing. Lufthansa Technik has used Titomic technology for aircraft-part repair for several years and is now expanding that capability at its Hamburg facility.

This suggests that cold spray has progressed beyond technical evaluation into an established maintenance workflow. Repair is especially attractive because it can restore high-value components without the thermal distortion associated with welding or melt-based additive processes.

The commercial value will depend on whether similar maintenance organizations adopt the same workflow and whether Titomic can generate recurring service, consumables and system-upgrade revenue from the installed base.

Royal NLR expands the allied aerospace pathway

Royal NLR’s order covers low-, medium- and high-pressure systems. That breadth allows the Dutch aerospace research center to evaluate repair, coatings and additive-manufacturing applications across a wider range of materials and component requirements.

The order improves Titomic’s position inside the European aerospace and defense ecosystem, but research-center adoption is not the same as production-scale demand. The key follow-through would be customer programs that move from application development into certified fleet or defense use.

NASA and the U.S. military create pathways—not guaranteed revenue

The NASA Space Act Agreement and military CRADA are strategically valuable because they create formal channels for testing, information exchange and joint development.

They should not be treated as firm production contracts. Their economic value depends on whether evaluations generate funded programs, qualification milestones and repeat manufacturing or sustainment work.

The strongest near-term evidence remains Titomic’s paid defense-prime development contract. If that work progresses from manufacturing development into low-rate initial production, it would mark a more meaningful transition toward recurring defense revenue.

Cold spray may be strongest in repair and sustainment

Titomic’s technology is often discussed as an additive-manufacturing platform, but its most commercially immediate applications may be coatings, corrosion protection and repair.

These markets already have urgent operational problems: aging fleets, long replacement lead times, material degradation and limited spare-part availability. Cold spray can deposit material without melting the substrate, making it useful where heat input would damage the component.

That focus could shorten commercialization timelines compared with entirely new structural components, which usually require longer qualification cycles.

The financial gap remains large

For the six months ended December 2025, Titomic reported A$4.0 million in customer revenue and A$5.3 million in total revenue, against a net loss of A$17.9 million.

The company is deliberately investing in U.S. production capacity, personnel and certification, but the numbers show how far revenue must scale before the model becomes self-sustaining.

The strengthened cash balance reduces immediate financing risk. It does not remove dilution risk if customer programs convert more slowly than expected.

What would prove the thesis?

Lufthansa or other MRO customers place further repeat orders.
Royal NLR programs progress into funded aerospace or defense deployments.
The defense-prime development contract converts into low-rate production.
NASA or military research agreements produce paid follow-on work.
Repair and sustainment revenue becomes recurring rather than project-based.
Gross margin improves as U.S. and European facilities gain utilization.
Annual revenue grows materially faster than operating expenses.
Operating cash burn declines toward management’s 2027 breakeven objective.

What would break the thesis?

Research agreements fail to produce funded programs.
Defense development work remains prototype-scale.
Customer orders stay small and irregular.
New facilities remain underutilized.
Operating expenses continue to outpace revenue growth.
Additional capital raises create substantial dilution.
Qualification timelines extend beyond customer funding cycles.

Research conclusion

Titomic’s 2026 developments show broader and more credible market access. A repeat Lufthansa order, a paid Royal NLR system package and formal NASA and military pathways strengthen the commercial thesis.

But Titomic is not yet a scaled defense manufacturer. It remains a technology company investing ahead of revenue.

The decisive transition will occur when today’s evaluations and development contracts convert into repeat production, sustainment and aftermarket cash flows.